Zynerba Pharmaceuticals Stock Number Of Shares Shorted
| ZYNEDelisted Stock | USD 0.36 0.01 2.70% |
Zynerba Pharmaceuticals fundamentals help investors to digest information that contributes to Zynerba Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Zynerba Stock. The fundamental analysis module provides a way to measure Zynerba Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Zynerba Pharmaceuticals stock.
Zynerba |
Zynerba Pharmaceuticals Company Number Of Shares Shorted Analysis
Zynerba Pharmaceuticals' Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
More About Number Of Shares Shorted | All Equity Analysis
Shares Shorted | = | Shorted by Public | + | by Institutions |
Current Zynerba Pharmaceuticals Number Of Shares Shorted | 419.98 K |
Most of Zynerba Pharmaceuticals' fundamental indicators, such as Number Of Shares Shorted, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Zynerba Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
CompetitionBased on the recorded statements, Zynerba Pharmaceuticals has 419.98 K of outstending shares currently sold short by investors. This is 86.87% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The number of shares shorted for all United States stocks is 91.07% higher than that of the company.
Zynerba Number Of Shares Shorted Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Zynerba Pharmaceuticals' direct or indirect competition against its Number Of Shares Shorted to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Zynerba Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Zynerba Pharmaceuticals by comparing valuation metrics of similar companies.Zynerba Pharmaceuticals is currently under evaluation in number of shares shorted category among its peers.
Zynerba Fundamentals
| Return On Equity | -0.87 | |||
| Return On Asset | -0.45 | |||
| Current Valuation | 28.33 M | |||
| Shares Outstanding | 53.94 M | |||
| Shares Owned By Insiders | 6.07 % | |||
| Shares Owned By Institutions | 12.12 % | |||
| Number Of Shares Shorted | 419.98 K | |||
| Price To Earning | (3.84) X | |||
| Price To Book | 0.54 X | |||
| Price To Sales | 1,153 X | |||
| EBITDA | (34.62 M) | |||
| Net Income | (35.04 M) | |||
| Cash And Equivalents | 62.49 M | |||
| Cash Per Share | 1.44 X | |||
| Total Debt | 334.43 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 6.89 X | |||
| Book Value Per Share | 0.57 X | |||
| Cash Flow From Operations | (23.03 M) | |||
| Short Ratio | 0.26 X | |||
| Earnings Per Share | (0.80) X | |||
| Target Price | 1.25 | |||
| Number Of Employees | 25 | |||
| Beta | 1.19 | |||
| Market Capitalization | 70.12 M | |||
| Total Asset | 55.52 M | |||
| Retained Earnings | (274.52 M) | |||
| Working Capital | 45.6 M | |||
| Current Asset | 43.42 M | |||
| Current Liabilities | 3.94 M | |||
| Net Asset | 55.52 M |
About Zynerba Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Zynerba Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Zynerba Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Zynerba Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Other Consideration for investing in Zynerba Stock
If you are still planning to invest in Zynerba Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Zynerba Pharmaceuticals' history and understand the potential risks before investing.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine |